First Author: R.Casaroli Marano SPAIN
Co Author(s): E. Cordero Fernandez A. Serrano A. Socorro J. Giralt C. Xavier T. Josep
Back to previous
To analyze the efficacy and safety of cataract surgery in patients with neo-vascular age-related macular degeneration (wAMD) previously treated with inhibitors of vascular endothelial growth factor (VEGF).
Single ophthalmological public centre at Barcelona.
A longitudinal retrospective descriptive study was carried out by reviewing the medical records, selecting those patients with wAMD who underwent cataract surgery and had been treated previously with anti-VEGF. It was required a minimum of 3 months of macular stability before the intervention, and a minimum follow-up of 1 year. Data about the best corrected visual acuity (BCVA) was collected prior to cataract surgery, at one year and at the last control visit. The drug applied and number of the intravitreal anti-VEGF injections before surgery were collected, as well as the intraoperative or postoperative injections. The time from diagnosis of wAMD to intervention, the existence of ocular comorbidity and post-surgical complications were also evaluated.
We analyzed 28 eyes from 25 patients. BCVA before cataract surgery was in average 0.19 ± 0.17, improving to 0.30 ± 0.26 (p = 0.05) after one year of intervention, and remained at 0.28 ± 0.25 (p = 0.04) in the last ophthalmological control. However, we did not see statistically significance between the BCVA at one year and BCVA at the last visit (p = 0.06). Only 7.1% of the eyes presented post-surgical complications, and 28.6% of them showed recurrence of retinal neovascularization during the post-surgical follow-up time (34.03 ± 19.59 months), requiring anti-VEGF treatment. The 89.3% of the studied eyes showed some macular change after surgery, although 76% of them occurred after 12 months after surgery.
Our results suggest that cataract surgery performed in patients with wAMD, previously treated with anti-VEGF drugs, is safe and beneficial regarding visual function.